Minus Anthracycline or Short-Term Versus Epirubicin and Cyclophosphamide Followed by Paclitaxel Regimen for Adjuvant Breast Cancer Therapy

NCT01314833 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1570

Enrollment

OTHER

Sponsor class

Conditions

Primary Breast Cancer

Interventions

DRUG: Docetaxel Cyclophosphamide
DRUG: Cyclophosphamide Fluorouracil Epirubicin Docetaxel
DRUG: Epirubicin Cyclophosphamide Paclitaxel

Sponsor

Fudan University

Collaborators

[object Object]